Testing a new treatment for aggressive breast cancer
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
This study is looking for patients with aggressive breast cancer, especially those with triple negative breast cancer or who haven't responded to regular treatments, to try a new drug that targets a specific protein made by cancer cells, which could help slow down tumor growth.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | A and G Pharmaceutical, INC. NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10252075 on NIH RePORTER |
What this research studies
This research focuses on developing a new targeted therapy for patients with aggressive forms of breast cancer, specifically triple negative breast cancer (TNBC) and those resistant to standard treatments. The approach involves using a drug called anti-GP88 (AG1) that blocks a glycoprotein produced by cancer cells, which is linked to tumor growth. Patients will undergo a tissue test to identify if their tumors express GP88, and if so, they may participate in a clinical trial to assess the safety and effectiveness of AG1. Additionally, a blood test will be used to monitor treatment responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with aggressive triple negative breast cancer or those resistant to anti-estrogen therapies.
Not a fit: Patients with early-stage or non-aggressive forms of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new targeted treatment option that improves survival rates for patients with aggressive breast cancer.
How similar studies have performed: While the approach of targeting GP88 is innovative, similar targeted therapies have shown promise in other cancer types, suggesting potential for success in this area.
Where this research is happening
Columbia, United States
- A and G Pharmaceutical, INC. — Columbia, United States (Active)
Researchers
- Principal investigator: Serrero, Ginette — A and G Pharmaceutical, INC.
- Study coordinator: Serrero, Ginette
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.